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A B S T R A C T
Background
Mucopolysaccharidosis II, also known as Hunter syndrome, is a rare, X-linked disease caused by a deficiency of the lysosomal enzyme
iduronate-2-sulfatase, which catalyses a step in the catabolism of glycosaminoglycans. The glycosaminoglycans accumulate within
tissues affecting multiple organs and physiologic systems. The clinical manifestations include neurologic involvement, severe airways
obstruction, skeletal deformities and cardiomyopathy. The disease has a variable age of onset and variable rate of progression. In
those with severe disease, death usually occurs in the second decade of life, whereas those individuals with less severe disease may
survive into adulthood. Enzyme replacement therapy with intravenous infusions of idursulfase has emerged as a new treatment for
mucopolysaccharidosis type II. This is an update of a previously published version of this review.
Objectives
To evaluate the effectiveness and safety of enzyme replacement therapy with idursulfase compared to other interventions, placebo or
no intervention, for treating mucopolysaccharidosis type II.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Trials Register (date of last search 23 November 2015).
We also searched Embase, PubMed and the Literature Latino-Americana e do Caribe em Ciências da Saúde (LILACS) (date of last
search 28 November 2015).
Selection criteria
Randomised and quasi-randomised controlled trials of enzyme replacement therapy with idursulfase compared to no intervention,
placebo or other options (e.g. behavioral strategies, transplantation).
Data collection and analysis
Two authors independently screened the trials identified, appraised quality of papers and extracted data.
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Main results
One study (96 male participants) met the inclusion criteria, although the primary outcome of this review - z score for height and weight,
was not assessed in the study. This trial was considered to be of overall good quality. Following 53 weeks of treatment, participants in
the weekly idursulfase 0.5 mg/kg group demonstrated a significant improvement rate compared with placebo for the primary outcome:
distance walked in six minutes on the basis of the sum of ranks of change from baseline, mean difference 37.00 (95% confidence interval
6.52 to 67.48). The every-other-week idursulfase 0.5 mg/kg group also showed an improvement, which was not significant compared
with placebo, mean difference 23.00 (95% confidence interval -4.49 to 50.49). After 53 weeks, there was no statistical significance
difference in per cent predicted forced vital capacity between the three groups and absolute forced vital capacity was significantly
increased from baseline in the weekly dosing group compared to placebo, mean difference 0.16 (95% confidence interval CI 0.05 to
0.27). No difference was observed between the every-other-week idursulfase 0.5 mg/kg group and placebo.
In addition, liver and spleen volumes and urine glycosaminoglycan excretion were significantly reduced frombaseline by both idursulfase
dosing regimens. Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in
31.7% of participants at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels.
Authors’ conclusions
The current evidence is limited. While the randomised clinical trial identified was considered to be of good quality, it failed to describe
important outcomes. It has been demonstrated that enzyme replacement therapy with idursulfase is effective in relation to functional
capacity (distance walked in six minutes and forced vital capacity), liver and spleen volumes and urine glycosaminoglycan excretion
in people with mucopolysaccharidosis type II compared with placebo. There is no available evidence in the included study and in the
literature on outcomes such as improvement in growth, sleep apnoea, cardiac function, quality of life and mortality. More studies are
needed to obtain more information on the long-term effectiveness and safety of enzyme replacement therapy.
P L A I N L A N G U A G E S U M M A R Y
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Review question
We reviewed the evidence about the effect and safety of enzyme replacement therapy with idursulfase compared to other interventions,
placebo (’dummy treatment’) or no intervention, for treating people withmucopolysaccharidosis type II. This is an update of a previously
published version of this review.
Background
Hunter syndrome or mucopolysaccharidosis II is a rare genetic disease that occurs when an enzyme that the body needs is either
missing or malfunctioning. The body doesn’t have adequate supplies of this enzyme to break down certain complex molecules, so these
molecules build up in harmful amounts in certain cells and tissues. The build-up that occurs in Hunter syndrome eventually causes
permanent, progressive damage affecting appearance, mental development, organ function and physical abilities. Hunter syndrome
appears in children as young as the age of two years and it nearly always occurs in males. In the past, treatment of Hunter syndrome
has been limited to the relief of symptoms and complications. Enzyme replacement therapy with idursulfase aims to replace iduronate-
2-sulfatase, the enzyme that is deficient or absent in people with Hunter syndrome. However, given its high cost it is essential to assess
how effective and safe this treatment is.
Search date
The evidence is current to: 23 November 2015.
Study characteristics
The review included one study with 96 males with Hunter syndrome aged between 4.9 and 30.9 years of age. The trial compared
idursulfase 0.5mg/kg given either weekly or every-other week, or weekly infusions of placebo (a substance which contains nomedication)
and people were selected for one treatment or the other randomly. The study lasted 53 weeks.
Key results
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Current evidence is limited given there was only one randomised clinical trial found in themedical literature. As compared with placebo,
enzyme replacement therapy with idursulfase in people with Hunter syndrome, led to some improvement in the individuals’ ability
to walk and a reduction in the excretion of abnormal mucopolysaccharides in the urine. To date there is no evidence available in the
literature showing that treatment reduces complications of the disease related to quality of life and mortality.
Quality of the evidence
This trial was considered to be of overall good quality.
B A C K G R O U N D
Description of the condition
Mucopolysaccharidosis II (MPS II or Hunter syndrome) belongs
to a group of inherited diseases of glycosaminoglycan (GAG)
catabolism calledmucopolysaccharidoses. TheGAGs are oligosac-
charide components of the proteoglycans, macromolecules re-
sponsible for the integrity and function of connective tissue. Mu-
copolysaccharidoses are caused by a lysosomal enzyme deficiency
for the stepwise degradation of the GAGs. All of themucopolysac-
charidoses are of recessive autosome inheritance, except MPS II,
which is anX-linked recessive disease. The syndromewas described
by Charles Hunter in 1917 and is the result of a deficiency of
iduronate-2-sulfatase (I2S), with consequent increase of the uri-
nary concentration of the GAGs dermatan sulphate and heparan
sulphate. The clinical phenotype of MPS II is characterised by
progressive pathological lysosomal storage of GAGs in nearly all
cell types, tissues and organs. The iduronate 2-sulfatase gene is lo-
cated on chromosome Xq28, and more than 350 mutations have
been identified to date, including different deletions, splice-site
and point mutations. This genetic heterogeneity may explain the
high degree of clinical heterogeneity in MPS II (Martin 2008;
Wraith 2008a).
This is a rare disease with an estimated incidence of approximately
1 in 162,000 live births. Although males are predominantly af-
fected, a small number of affected females have been described
(Meikle 1999; Tuschl 2005). This is a variable, progressive, mul-
tisystem disease and should be regarded as a continuum between
two extremes (severe and attenuated). Two-thirds of individuals
present central nervous system (CNS) involvement, representing
themore severe form, with clinical features appearing between two
and four years of age. In these cases, the progressive neurologic
involvement is prominent and leads to severe mental impairment;
death usually occurs in the first or second decade of life, usually
because of obstructive airway disease or cardiac failure (or both)
associated with loss of neurologic function. At the opposite end
of the spectrum, clinical signs and symptoms have a slightly later
onset and the neurologic dysfunction may be minimal, but with
obvious somatic involvement, and longer survival (Wraith 2008a).
Data from the ’Hunter Outcome Survey’ (HOS), the only large-
scale, multinational observational study of people with MPS II,
showed that median age at death was significantly lower in those
with cognitive involvement compared with those without cogni-
tive involvement (11.7 versus 14.1 years; P = 0.024) (Jones 2008).
The most common clinical signs and symptoms include dysosto-
sis multiplex with decreased range of joint motion, coarse facial
features, enlarged tongue, hearing loss, abnormal dentition, up-
per airway obstruction with or without sleep apnoea, restrictive
lung disease, hepatosplenomegaly, cardiomyopathy, skeletal defor-
mities, and severe short stature (Young 1983).
The development of children with MPS II seems normal in the
first months of life, but the outcome is highly changeable. Even
in individuals with attenuated disease, cranial magnetic resonance
imaging (MRI) scans are often grossly abnormal, with extensive
white matter changes as well as dilated perivascular spaces, despite
apparently normal intellectual skills. Individuals with more severe
MPS II also appear normal at birth, and early development may
be normal. Some individuals fail hearing screening tests in the
first year, and speech delay is not unusual in those more severely
affected. By 18 to 24 months developmental delay is usually ap-
parent. Most individuals make very slow progress after this stage,
with a developmental plateau beginning between three and five
years of age. Unlike children with severe MPS I, who are usually
placid, more severely affected children with MPS II can be hy-
peractive and aggressive. One of the most important limitations
beside the neurologic involvement in individuals suffering from
MPS II, is the impact that the progressive physical abnormalities
have on their quality of life. Due to a combination of the bone dis-
ease, decreased respiratory capacity and impaired cardiac function,
they suffer from chronic, severely diminished endurance.With the
disease progression their ability to walk even short distances may
be lost and eventually many people become wheelchair-bound. By
the time of death in their second decade, most individuals with
CNS involvement show severe learning difficulties and are depen-
dant on care providers for all their needs (Wraith 2008a).
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The measurement of urinary GAGs (heparan and dermatan sul-
phate) is the usual first screening test for MPS II. As in almost
all cases of MPS, the total urinary GAG level is increased. How-
ever, this is not diagnostic of MPS II, so additional tests must
be performed. Futhermore, a negative urine GAG test does not
necessarily rule out a diagnosis of MPS II, because false-negative
results can occur as a result of a lack of sensitivity of the testing
method (de Jong 1992). Definitive diagnosis is established by en-
zyme assay in leukocytes, fibroblasts or plasma, using substrates
specific for I2S. Absent or low I2S activity in males is diagnostic of
MPS II, provided that multiple sulphatase deficiency is excluded
by finding normal activity of another sulphatase. Absolute enzyme
activity cannot be used to predict the severity of the phenotype.
Mutation analysis may be used to confirm Hunter syndrome in
males. However, it is difficult to establish a genotype-phenotype
correlation to provide an indication of the likely prognosis, this
is because individuals carrying the same alterations may present
different phenotypes, suggesting that others factors may modulate
the clinical phenotype (Kresse 1982;Martin 2008; Neufeld 2001).
As the definition of effective treatment for MPS II is “an improve-
ment in or a prevention of progression of disease activity as in-
dicated by a stabilisation in clinical condition associated with an
improvement in the abnormalities present at baseline” (Vellodi
2007), the primary endpoints for the evaluation of interventions
for the treatment of this condition should reflect improvement in
important signs and symptoms observed in the disease, such as a
change in the speed of growth and in the impairment of cardiac
and respiratory system.
The usual management of MPS II has been palliative and focused
on the treatment of signs and symptoms. Care for the person
with MPS II involves a multidisciplinary approach and includes
paediatricians, neurologists, orthopedists, otolaryngologists, oph-
thalmologists, and occupational and physical therapists, as well
as geneticists and counsellors (National Horizon Scanning Centre
2005). Hemapoietic stem cell transplantation (HSCT) by bone
marrow transplantation, human amnionmembrane implantation,
fibroblast transplantation, serum or plasma infusion has been sug-
gested as a means of providing donor cells capable of expressing
I2S, but the results are disappointing and long-term outcomes are
limited, therefore, HSCT is not currently recommended for indi-
viduals with MPS II (Martin 2008).
Description of the intervention
Recently idursulfase (Elaprase®, Shire Human Genetic Therapies,
Inc, Cambridge, MA), a recombinant human I2S produced in a
human cell line, was approved in the United States of America and
the European Union for the treatment of MPS II.
How the intervention might work
The rationale for therapy is that exogenous I2S would replace the
I2S that is deficient in peoplewithMPS II and either stop or reverse
disease progression. Idursulfase is produced in a continuous hu-
man cell line and is a purified formof the natural lysosomal enzyme
I2S.Mannose-6-phosphate (M6P) residues on the oligosaccharide
chains of the glycoprotein enzyme and allows specific binding of
idursulfase to M6P receptors on the cell surface, leading to cellu-
lar internalisation and targeting of the enzyme to lysosomes, and
subsequent catabolism of accumulated GAGs (Wraith 2008b).
Why it is important to do this review
There is no definitive treatment for people diagnosed with MPS
II. The appearance of a promising therapeutic strategy, idursulfase,
makes it necessary to map the knowledge in this area based on
the rigor inherent to systematic reviews by considering relevant
aspects of the effectiveness and safety of this therapeutic strategy
for relevant clinical issues.
The current publication is a minor update of a Cochrane review
first published in 2011 and again in 2014 (da Silva 2011; da Silva
2014).
O B J E C T I V E S
To evaluate the effectiveness and safety of enzyme replacement
therapy with idursulfase compared to other interventions, placebo
or no intervention, for treating mucopolysaccharidosis type II.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised andquasi-randomised controlled clinical trials of par-
allel or cross-over design.
Types of participants
Individuals with MPS II (Hunter syndrome) of any age and any
degree of disease severity. Diagnosis should be established by en-
zyme assay in leukocytes, fibroblasts or plasma, using substrates
specific for I2S.
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Types of interventions
Enzyme replacement therapywith idursulfase in any amount given
for a period of at least one month compared to:
• no intervention;
• placebo;
• other options (e.g. behavioral strategies, transplantation).
Types of outcome measures
Following further advice from the Cochrane Cystic Fibrosis and
Genetic Disorders Editorial Team, we have made post hoc changes
to the outcomes. Previously listed as primary outcomes - ’left
ventricular mass index’ and ’overnight apnoea-hypopnoea index
(AHI)’ have been re-allocated to secondary outcomes. The six-
minute walk test (6MWT) has been re-allocated from secondary
outcomes to primary outcomes. Given that MPS II is a disease
with multiorgan and multisystem involvement, a variable age of
onset and a variable rate of progression, we found the choice of
representative outcomes a challenge. Since appropriate growth is
a key clinical feature in children and this is altered in all forms of
MPS II, we selected z score of weight and height as the primary
outcome (Martin 2008; Wraith 2008a). As studies may include
adults, the functional capacity test 6MWT was also selected as a
primary outcome because this standardized test is the most often
used to measure functional capacity (ATS 2002). Outcomes that
represent changes in other organs and systems are listed as sec-
ondary.
Primary outcomes
1. Z scores for
i) height
ii) weight
2. Six-minute walk test (6MWT)
Secondary outcomes
1. Lung function
i) forced expiratory volume at one second (FEV1)
ii) forced vital capacity (FVC)
iii) any other measure of lung function (e.g. Rint)
2. Overnight apnoea-hypopnoea index (AHI)
3. Left ventricular mass index
4. Joint mobility score (using a validated scoring system)
5. Liver and spleen volume (measured by abdominal MRI)
6. Quality of life (using a validated scoring system)
7. Pain (using a validated scoring system e.g. visual analogue
scales (VAS))
8. Rate of hospitalizations
9. Resources required for home care support
10. Changes in glycosaminoglycans (GAGs) urinary excretion
11. Developmental score
12. Audiologic assessment (e.g. pure tone audiogram, distortion
product otoacoustic emission (DPOE), evoked responses)
13. Age at death
14. Adverse effects (AE) and toxicity of treatment
Search methods for identification of studies
Electronic searches
There was no language restriction and the trials were identified
from the sources listed below.
We identified relevant trials from the Cochrane Cystic Fibrosis
andGeneticDisordersGroup’s InbornErrors ofMetabolismTrials
Register using the term: mucopolysaccharidosis.
This register was compiled from electronic searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) (up-
dated each new issue of The Cochrane Library), weekly searches of
MEDLINE and the prospective handsearching of the Journal of
Inherited Metabolic Disease. Unpublished work were identified by
searching through the abstract books of the Society for the Study
of Inborn Errors of Metabolism conference and the SHS Inborn
Error Review Series. For full details of all searching activities for
the register, please see the relevant section of the Cystic Fibrosis
and Genetic Disorders Group Module.
We also searched Embase (1980 to 23 November 2015), PubMed
(1980 to 23 November 2015) and the Literature Latino-Amer-
icana e do Caribe em Ciências da Saúde - LILACS (1982 to
23 November 2015). The search strategy was composed of the
terms ’enzyme replacement therapy’ and ’Mucopolysaccharidosis
II’. We searched with both, subject headings and free text words
(see Appendix 1; Appendix 2; Appendix 3).
Date of most recent search of the Cochrane Cystic Fibrosis and
Genetic Disorders Group’s Inborn Errors of Metabolism Trials
Register: 23 November 2015.
Searching other resources
Reference lists of any identified relevant studies were scrutinized
for additional citations.
Data collection and analysis
Selection of studies
Two authors (EMKS and LAS) independently screened the studies
identified by the literature search. When disagreements occurred
they consulted a third author (RBA) and did not include data until
they reached a consensus.
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Data extraction and management
Two authors (EMKS and LAS) extracted data independently; they
resolved discrepancies in the results by discussion. The authors
used a standard form to extract the following information: char-
acteristics of the study (design, method of randomisation); partic-
ipants; interventions; and outcomes (types of outcome measures,
timing of outcomes, adverse events).
The authors planned to report outcomes at up to and including
three months, over three months and up to six months, over six
months and up to twelve months and then annually thereafter.
They also planned to consider additional follow-up data recorded
at more than 12months. Given only one trial is currently included
they have reported these data at 53 weeks, as within the trial.
The included trial reported standard errors (SE) ; the authors con-
verted these to standard deviations (SD) (SD = SE x square root
of n).
Assessment of risk of bias in included studies
In order to assess the risk of bias, two review authors independently
assessed the quality of the studies included in the review according
to the criteria described in the Cochrane Handbook For Systemtic
Review of Interventions (Higgins 2011a).
They assessed the following domains as having either a low, unclear
or high risk of bias.
1. Was the sequence generation adequate?
2. Was allocation adequately concealed?
3. Was knowledge of the allocated interventions adequately
prevented during the study?
4. Were incomplete outcome data adequately addressed?
5. Are reports of the study free of suggestion of selective
outcome reporting?
6. Was the study apparently free of other problems that could
put it at a high risk of bias?
The authors reported these assessments for each individual study
in the ’Risk of bias’ table in the section ’Characteristics of included
studies’.
If necessary, for future updates, they plan to contact the study
author(s) to seek clarification in case of uncertainty over data.
Measures of treatment effect
For dichotomous variables, the authors calculated the risk ratio
(RR) and 95% confidence intervals (CIs). For continuous out-
comes, they calculated the mean difference (MD) and 95% CIs.
In this review the authors did not identify studies in which the
authors did not publish or make available the necessary informa-
tion to be included in the review. For further studies identified
in subsequent updates of this review, the authors will insert any
data from primary studies which are not parametric (e.g. effects
reported as medians, quartiles, etc) or without sufficient statistical
information (e.g., SDs, number of participants, etc) into an ’Ad-
ditional table’.
Unit of analysis issues
The unit of analysis is based on the individual participant (unit to
be randomised for interventions to be compared), i.e. the num-
ber of observations in the analysis should match the number of
individuals randomised. The authors did not identify trials with a
cross-over design, if in subsequent updates they include such trials,
they will use only first-arm data (before participants have crossed
over the treatments) (Elbourne 2002).
Dealing with missing data
Irrespective of the type of data, the authors reported dropout rates
in the Characteristics of included studies table and they used in-
tention-to-treat analysis (Higgins 2011b).
Assessment of heterogeneity
As the authors only included one study they did not evaluate
heterogeneity. In future updates, they will qualify inconsistency
among the pooled estimates using the I2 = [(Q - df )/Q] x 100%
test, where Q is the chi-squared statistic and df its degrees of free-
dom. This illustrates the percentage of the variability in effect es-
timates resulting from heterogeneity rather than sampling error
(Higgins 2003; Higgins 2011a). The thresholds for the interpre-
tation of I2 will be as follows: 0% to 25% low heterogeneity; 25%
to 75% moderate heterogeneity; and more than 75% significant
heterogeneity (Higgins 2003).
Assessment of reporting biases
In future updates of this review, if a sufficient number of studies
(at least 10) are included, the authors will assess publication bias
by drawing a funnel plot (trial effect versus trial size).
Data synthesis
Qualitative information
The authors synthesized qualitative information relative to meth-
ods, risk of bias, description of participants and outcome mea-
sures and inserted this information in the table of Characteristics
of included studies.
Quantitative information
For dichotomous variables, the authors calculated theRRand 95%
CIs. For continuous variables, we calculated the MD and 95%
CIs.
In subsequent updates of this review, if continuous data relate to
the same outcome, but are measured with different instruments
(different and not interchangeable units of measure), the authors
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will pool these data using the standardisedmeandifference (SMD).
For all statistical methods when pooling data, they will report the
95% CIs. If they do not identify any significant heterogeneity,
theywill compute pooled estimates of the treatment effect for each
outcome under a fixed-effect model. Otherwise, if they identify
significant heterogeneity, they will perform a random-effects anal-
ysis.
Subgroup analysis and investigation of heterogeneity
In subsequent updates of this review, If the authors find signifi-
cant heterogeneity, they will investigate the possible causes of this
further by exploring the impact of the condition of the individuals
(i.e. severity of disease, duration of treatment). If they find sources
of heterogeneity and if there are sufficient data, they will conduct
meta-analyses by subgroups (by types of dosage and duration of
intervention, disease stage, age at onset).
Sensitivity analysis
As only one study was included in this review, the authors did
not perform any sensitivity analyses, but will do so if there are an
adequate number of studies included in future updates. If, in the
future, they are able to perform a sensitivity analysis, they will do
so with an aim to explore possible causes of heterogeneity and the
robustness of the results.
We will include the following factors in any sensitivity analysis,
separating studies according to:
1. allocation concealment quality (low, unclear or high risk);
2. blinding of participants, caregiver and outcome assessment
(low, unclear or high risk, or not performed);
3. rates of withdrawal for each outcome;
4. length of follow-up;
5. age of participants;
6. disease severity.
R E S U L T S
Description of studies
Results of the search
There were 202 records identified by the searches: MEDLINE
(PubMed): 103 references to studies; Cochrane Cystic Fibrosis
and Genetic Disorders Group’s Trials Register: 43 references; EM-
BASE: 60 references; LILACS: 3references. The authors also scru-
tinised the bibliographical references of these papers for further
potentially eligible studies and found no additional references. Af-
ter closer examination of the titles and abstracts of these refer-
ences, all but eight studies were subsequently excluded from fur-
ther analysis. If possible, full text copies of these remaining stud-
ies were obtained and were then subjected to further assessment.
Following the verification of the whole studies, only one of them
fulfilled all the inclusion criteria of this review (Muenzer 2006)
and six studies were excluded (Muenzer 2007; Gutiérrez-Solana
2007; Tylki-Szymanska 2008; Sohn 2013) (Figure 1). An addi-
tional study is ongoing (NCT02055118).
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Figure 1. Study flow diagram.
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Included studies
Trial design
The included study was a multicentre, multi-national, dou-
ble-blind, randomised, placebo-controlled, 53-week, phase II/III
study of the efficacy and safety of idursulfase 0.5 mg/kg admin-
istered either weekly or every-other week (EOW) in people with
MPS II (Muenzer 2006).
Participants
The study included 96 people with MPS II. The biochemical
evidence of MPS II included a documented deficiency in the I2S
enzyme activity of less than or equal to 10% of the lower limit
of the normal range measured in plasma, fibroblasts or leukocytes
combined with a normal enzyme activity level of another sulfatase.
All participants were required to reproducibly perform pulmonary
function testing and have an abnormal FVC of less than 80% of
predicted. Those individuals who had a tracheotomy or who had
received a bone marrow or cord blood transplant were excluded
from the study. All 96 randomised participants were male between
the ages of 4.9 and 30.9 years. The mean (SD) age of participants
in this studywas 13.1 years (1.22), 14.4 years (1.20) and 15.1 years
(1.11) for the placebo, idursulfase 0.5mg/kgEOWand idursulfase
0.5 mg/kg weekly groups respectively. Nearly 45% of participants
in the study were five to 11 years old and 25% were 19 years of age
or older. There was no significant difference of age distribution
among the three groups. Participants were also stratified according
disease score, calculated using the baseline results of the 6MWT
and the per cent predicted FVC (% predicted FVC).
Interventions
The 96 participants were randomised in three groups: placebo (n
= 32); idursulfase 0.5 mg/kg weekly (n = 32); and idursulfase 0.5
mg/kg EOW (n = 32). Infusions were given over a three-hour
period and participants were discharged one hour after completing
each infusion provided that they remained clinically stable.
Outcomes
The primary efficacy assessment of the included study was a com-
parison between the placebo and weekly idursulfase group for the
change from baseline to week 53 in a single, two-component com-
posite variable combining % predicted FVC as a measure of respi-
ratory function and 6MWT as ameasure of physical functional ca-
pacity. The change from baseline to week 53 in % predicted FVC
and 6MWT for each participant was calculated. Within each pa-
rameter the changes were ranked irrespective of treatment group,
with the lowest change value assigned a rank of 1, the next lowest
a rank of 2, and so forth. The two-component composite score
for each participant was calculated by summing the ranks of the
two individual components. The 6MWT was conducted in ac-
cordance with American Thoracic Society guidelines (ATS 2002).
The secondary efficacy outcome measurements were: passive joint
range of motion (JROM); liver and spleen volume by MRI and
urinary GAG levels. Data were analysed using analysis of covari-
ance with the treatment groups and study region fitted as factors
and baseline participant age and baseline disease score as covariate.
All analyses were performed by intention-to treat (ITT) and each
variable was quantified as a change from the baseline value.
Excluded studies
A total of six studies were excluded (Gutiérrez-Solana 2007;
Muenzer 2007; Muenzer 2016; Sohn 2013; Sohn 2015; Tylki-
Szymanska 2008). One because it was an abstract reporting partial
results of an ongoing case-series study (Tylki-Szymanska 2008);
one because it was a phase I/II clinical trial that evaluated safety
and dosing requirements (Muenzer 2007); one because it was a
narrative review (Gutiérrez-Solana 2007); and one because it was
a clinical trial phase I/II comparing a new formulation of the en-
zyme, Idursulfase beta, in two doses with the formulation of idur-
sulfase currently available.
For further information, please refer to the Characteristics of
excluded studies table.
Risk of bias in included studies
Allocation
Generation of randomisation sequence was not clear in the in-
cluded study and we assessed this to have an unclear risk of bias
(Muenzer 2006). Authors state that the randomisation was strati-
fied by age and total disease score at baseline.
Allocation concealment was not discussed in the study, which
therefore has been categorized as having an unclear risk of bias.
Blinding
The study was double-blind, and all participants received weekly
intravenous infusions. Participants randomised to EOW idursul-
fase dosing received placebo infusion during intervening weeks
to maintain blinding. The primary outcome assessment was con-
ducted by a professional who was not involved with the study. We
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therefore judged the study to have a low risk of bias for blinding
of participants, clinicians and outcome assessors.
Incomplete outcome data
Ninety-four (97.9%) of 96 participants completed one year of
treatment. The two participants, who did not complete one year
of treatment, died during the study: one participant in the placebo
group; and one participant in the idursulfase weekly group. Nei-
ther death was considered by the investigators to be related to the
study drug and analysis was done on an intention-to-treat basis.
We have therefore assessed this domain as having a low risk of bias.
Selective reporting
There is concern about selective reporting, due to important clin-
ical outcomes (e.g. z score of height and weight, left ventricular
mass index and overnight AHI) not being evaluated and we have
assessed this domain as having an unclear risk of bias.
Other potential sources of bias
We believe that the study was free of other problems that could
put it at a high risk of bias.
Effects of interventions
In the only included study, participants were randomised into
three groups, idursulfase 0.5 mg/kg weekly, EOW and placebo.
To evaluate the effect of each treatment the same placebo group
was presented in each subgroup in the meta-analyses graphs.
Primary outcomes
1. Z scores for height and weight
This outcome was not reported in the included study.
2. Six-minute walk test (6MWT)
Following 53 weeks of treatment, participants in the weekly idur-
sulfase 0.5 mg/kg group demonstrated a significant improvement
rate compared with placebo of the primary outcome: distance
walked in six minutes (6MWT) on the basis of change from base-
line, MD 37.00 (95% CI 6.52 to 67.48). The EOW idursulfase
0.5 mg/kg group also showed an improvement but this was not
significant compared with placebo, MD 23.00 (95% CI -4.49 to
50.49) (Analysis 1.1) (Figure 2).
Figure 2. Forest plot of comparison: 1 Idursulfase 0.5 mg/kg versus placebo, outcome: 1.1 Primary




This outcome was not reported in the included study.
b. FVC
Changes from baseline in % predicted FVC and absolute FVC
were reported (Muenzer 2006). After 53 weeks, there was no sta-
tistical significance difference in % predicted FVC between the
weekly idursulfase group and the placebo group, MD 2.70 (95%
CI -2.12 to 7.52) or in the EOW idursulfase group compared with
placebo group, MD -0.75 (95% CI -4.98 to 3.49) (Analysis 1.2).
Absolute FVC was significantly increased from baseline in the
weekly dosing group compared to placebo, MD 0.16 (95% CI
0.05 to 0.27) after 53 weeks. No difference was observed in abso-
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lute FVC between the EOW idursulfase group and placebo, MD
0.01 (95% CI -0.07 to 0.09) (Analysis 1.3).
c. Any other measure of lung function
No other measure of lug function was reported in the included
study.
2. Overnight apnea-hypopnea index (AHI)
This outcome was not reported in the included study.
3. Left ventricular mass index
This outcome was not reported in the included study.
4. Joint mobility score
The included study measured changes in passive joint range of
motion (JROM) (Muenzer 2006). The authors reported that there
were no significant differences between treatment groups but the
values observed were not published.
5. Liver and spleen volume
The study reported changes from baseline in the liver and spleen
volume determined by magnetic resonance imaging (MRI) us-
ing the same imaging protocol at all sites (Muenzer 2006). After
53 weeks, in the ITT population, liver volume changed statisti-
cally significantly in both idursulfase treatment groups (weekly
and EOW) compared with the change in the placebo group, MD
-24.50 (95% CI -28.94 to -20.06) and MD -23.20 (95% CI -
27.78 to -18.62) respectively (Analysis 1.5).
After 53 weeks in the ITT population, spleen volume were sig-
nificantly reduced in the idursulfase groups compared to placebo,
MD -32.30 (95% IC -41.79 to -22.81) in the weekly group; MD
-27.00 (95% IC -37.35 to -16.65) in the idursulfase EOW group
(Analysis 1.6).
6. Quality of life
This outcome was not reported in the included study.
7. Pain
This outcome was not reported in the included study.
8. Rate of hospitalizations
This outcome was not reported in the included study.
9. Resources required for home care support
This outcome was not reported in the included study.
10. Changes in glycosaminoglycans (GAGs) urinary
excretion
Changes from baseline in the GAGs urinary excretion were mea-
sured in the included study (Muenzer 2006). Urine GAGs levels
decreased in participants treated with either dosing regimen of
idursulfase and did not change significantly in participants treated
with placebo. At week 53, the changes in the GAGs levels in the
idursulfase groups (weekly and EOW) were significantly different
than that of the placebo group, MD -207.40 (95% CI -284.85 to
-129.95) and MD -173.20 (95% CI -240 to -105.56) respectively
(Analysis 1.7).
11. Developmental score
This outcome was not reported in the included study.
12. Audiologic assessment
This outcome was not reported in the included study.
13. Age at death
Two deaths occurred during the study (Muenzer 2006). A 24-year-
old male in the idursulfase weekly group developed a pulmonary
infection, respiratory insufficiency and had a cardiac arrest five
days after his first infusion, and he experienced a fatal cardiac arrest
seven days later. A second participant, a six-year-old male, who
was randomised to placebo developed streptococcus pneumonia
following his 34th dose of blinded-study medication, and suffered
a lung haemorrhage followed by a fatal cardiac arrest eight days
later. The study investigator did not consider either death as being
related to the study medication.
14. Adverse effects and toxicity of treatment
Noparticipant was reported towithdraw from the study due to ad-
verse effects (AE). The incidence of AEs were similar across treat-
ment groupswithin the trial (Muenzer 2006). Themost frequently
reported AEs during the study (with a excess incidence of at least a
9% compared with placebo in either idursulfase treated group) in-
cluded headache, nasopharyngitis, abdominal pain, arthralgia and
pruritus. All were considered to be consistent with those expected
to be seen in an untreated MPS II population. The majority of
AEs were reported as mild or moderate in severity in all groups.
Of the AEs considered to be possibly related to idursulfase treat-
ment, the most common were infusion-related. An infusion-re-
lated AE was defined as occurring within a day after the infusion
began and was judged by the investigator to be possibly or prob-
ably related to study treatment. A similar number of participants
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in each treatment group experienced one or more infusion-related
AEs during the study, RR 1.05 (95% CI 0.74 to 1.48) in the
weekly group compared to placebo and RR 1.05 (95% CI 0.74
to 1.48) in the EOW group (Analysis 1.8). The incidence of in-
fusion-related AEs was maximal between weeks four and 12 and
decreased in all three groups thereafter. Infusion-related AEs re-
ported in the placebo group were similar in nature and severity to
those in the idursulfase-treated groups. No participant withdrew
from the study because of infusion-related AEs.
A total of 49 serious adverse events (SAEs) occurred in 26 par-
ticipants during the study: nine participants in the placebo group
experienced a total of 18 SAEs; eight participants in the idursul-
fase EOW group experienced a total of 18 SAEs, RR 1.00 (95%
CI 0.65 to 1.54); and nine participants in the idursulfase weekly
group experienced a total of 13 SAEs, RR 0.72 (95% CI 0.43 to
1.21) (Analysis 1.9). The majority of these SAEs were considered
unrelated to the blinded study medication, although three partic-
ipants experienced SAEs that were considered by the investigators
to be probably or possibly related to the study drug.
Investigators detected IgG anti-idursulfase antibodies in 15 par-
ticipants (46.9%) in the idursulfase weekly group and in 15 par-
ticipants (46.9%) in the idursulfase EOW group. In two partici-
pants (one from each active treatment group) IgM antibodies were
found. The highest prevalence of IgG antibodies was seen at week
27 of the study, when 44.4% of the participants treated with idur-
sulfase were antibody-positive. After 53 weeks, 31.7% of partici-
pants in the idursulfase groups remained antibody-positive. The
reduction in urine GAG levels in antibody-positive participants
was approximately two-thirds of that seen in antibody-negative
participants. There was no association with the presence of anti-
bodies and AEs.
15. Other results
Composite score (% predicted FVC + 6MWT)
The efficacy endpoint in the trial included was change from base-
line to week 53 in a two-component composite score combin-
ing % predicted FVC as a measure of respiratory function and
the 6MWT as a measure of functional capacity (Muenzer 2006).
The two-component composite score of the idursulfase 0.5 mg/kg
weekly group was significantly higher than in the placebo group
in the intent-to-treat population, MD 18.96 (95% CI 6.28 to
31.64). A smaller difference was found for the idursulfase EOW
compared toplacebo groups in the intent-to-treat population,MD
12.86 (95% CI 0.77 to 24.95) (Analysis 1.4). The trial authors
reported that the responses between the two idursulfase treatment
groups were not significantly different, treatment difference being
10.84 ± 7.11, P = 0.1329).
D I S C U S S I O N
Summary of main results
The evidence available so far are limited to only one randomised
clinical trial (Muenzer 2006).The results of the study included in
this review show a short-term clinical benefit in people treated
with idursulfase compared with those treated with placebo. After
53 weeks of treatment, participants in the weekly idursulfase 0.5
mg/kg group demonstrated a statistically significant improvement
rate compared with placebo in the distance walked in six minutes
(6MWT), mean difference (MD) 37.00 (95% CI 6.52 to 67.48).
The every-other week (EOW) group also showed improvement
but not significant compared with placebo, MD 23.00 (95% CI -
4.49 to 50.49). There was no statistically significant difference in
per cent predicted forced vital capacity (FVC) between the three
groups and absolute FVCwas significantly increased frombaseline
in the weekly dosing group compared to placebo, MD 0.16 (95%
CI 0.05 to 0.27). In addition, urine glycosaminoglycan (GAG)
excretion and liver and spleen volumes were significantly reduced
from baseline by both idursulfase dosing regimens.
Idursulfase was generally well tolerated, and the majority of treat-
ment-emergent adverse events were consistent with the natural
history of untreated mucopolysaccharidosis (MPS) II. The most
common treatment-related adverse events were infusion related.
Idursulfase antibodies were detected in 31.7% of participants at
the end of the study and were related to smaller reduction in urine
GAG levels.
It is known that controlled studies in rare diseases are difficult to
be conducted and so far only results of observational studies are
available or ongoing. Results from two case series studies have been
published in recent years. One reports the experience of enzyme
replacement therapy with idursulfase in six children under five
years old (Alcade-Martín 2010). The children began treatment
with a mean age of 3.6 years and were followed for a mean period
of nine months. Decreased levels of urinary GAG were observed,
also some improvement in the volume of the liver and spleen; in
addition, joint mobility stabilized or improved during treatment.
Growth rate remained normal as expected; in untreated individ-
uals with MPS II, growth decelerates at around age four or five
years. With regards to safety, only mild drug-related infusion re-
actions were noted. The second study assessed the overall result
of enzyme replacement therapy on the growth of 18 participants
(nine under 10 years of age and nine over) followed for more than
three years (Schulze-Frenking 2011). All children under 10 years
of age (except one who had short stature at baseline) grew at nor-
mal rate during this period. Those over 10 years of age also showed
an increase in growth rate in the first two years of treatment, which
decreased in the third year. The authors suggested this may be due
to puberty. This study indicates that therapy may have a positive
effect on growth rate especially when initiated before 10 years of
age. In the latest searches undertaken for the update of this re-
view, a further observational study was identified (Jones 2013).
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The study investigated the effects of enzyme replacement therapy
with idursulfase on growth in people with MPS II enrolled in the
the Hunter Outcome Survey (HOS), a multinational database. A
total of 133 people (8 to 15 years of age at treatment start) with
data on height available on more than one occasion within 24
months of treatment start were included. Results showed that the
growth velocity after treatment was significantly improved com-
pared with before treatment. Analysis of a covariate showed a sig-
nificant negative influence on growth of mutation type (individu-
als with deletions or large rearrangements or nonsense mutations)
and age (12 to 15 years). Cognitive involvement, pubertal status
and functional classification were found not be be related to the
growth deficit or response to treatment.
It is noteworthy that in the Schulze-Frenking study one child
younger than 10 years of age, who already had short stature at
baseline, showed poor response in growth rate with treatment.
The study authors suggested that this may be related to the devel-
opment of antibodies (Schulze-Frenking 2011). The study does
not provide more data on safety and the proportion of individuals
who developed antibodies. From an immunological perspective,
the effect of neutralizing antibodies on efficacy is still to be fully
evaluated; therefore, no firm conclusions can be drawn about the
effect of neutralizing activity on the safety and efficacy of idursul-
fase.This factor should be carefully evaluated in other studies with
long-term follow-up,
While enzyme replacement therapy with idursulfase has been
shown to have biologic effects and may improve the functional
capacity in people with MPS II, the clinical significance of these
effects is not clear. The treatment improves the distance walked
in six minutes (6MWD) but the average improvement is small
with wide confidence intervals. Idursulfase has not been shown to
improve clinically relevant outcomes such as quality of life, pain,
rate of hospitalisation, resources required for home care support
and mortality.
Overall completeness and applicability of
evidence
The included study provided data on the efficacy and safety of
short-term (53 weeks) enzyme replacement therapy with idur-
sulfase for people with MPS II (aged five to 31 years). The re-
sults of the open-label extension study have recently been pub-
lished (Muenzer 2011). All individualswho completed the double-
blinded study received idursulfase 0.5 mg/kg weekly for two years.
There were no improvements in the per cent predicted FVC, only
in the absolute FVC, which probably reflected the growth that
has occurred in those younger than 18 years of age during treat-
ment, since this increase was not observed in those aged over 18
years. Increases in the 6MWT remained stable and mean liver and
spleen volumes remained reduced. Mean joint range of motion
improved only for the shoulder joint. All participants experienced
adverse effects, with 59.6% experiencing at least one drug-related
adverse effect, 53% an infusion-related adverse effect, 28.7% at
least one severe or life-threatening adverse effect. Neutralizing IgG
antibodies were detected in 27.1% of the participants at the end
of the extension study and seemed to attenuate the improvement
in pulmonary function. Participants in the study had to be able to
follow instructions and perform the test of the primary endpoint
(6MWT and per cent predicted FVC) which suggests that the in-
dividuals included were not representative of those with advanced
forms of the disease. The drug may achieve improvement of the
physical condition, a decrease of organomegaly and urinary excre-
tion of GAGs, but the overall benefit should be evaluated accord-
ing to global somatic involvement, overall rate of disease progres-
sion in central nervous system and on variables such as improved
length of survival.
Quality of the evidence
The quality of the included study was considered good, although
we note the absence within the study report of information as to
how both the allocation generation and concealment were per-
formed.
Potential biases in the review process
There is concern about selective reporting, due to important clini-
cal outcomes (e.g. growth velocity, left ventricular mass index and
overnight apnoea-hypopnoea index not being evaluated in the in-
cluded study.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current evidence is limited. While the randomised clinical
trial identified was considered of good quality, it failed to describe
important outcomes. It has been demonstrated that enzyme re-
placement therapy with idursulfase is effective in relation to func-
tional capacity (6MWT and per cent predicted FVC), liver and
spleen volumes and urine GAG excretion in people with MPS II
compared with placebo. There is no available evidence in the in-
cluded study or in the wider literature on outcomes such as sleep
apnoea, cardiac function, quality of life and mortality. More stud-
ies are needed to obtain more information on the long-term effec-
tiveness and safety of enzyme replacement therapy.
Implications for research
Further trials, including rigorous multi-domain follow up of par-
ticipants receiving treatment, are needed to determine the long-
term effects of enzyme replacement therapy. Clinically relevant
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outcomes should be assessed, such as improvements in cardiac
function, respiratory function, including sleep apnoea, stabiliza-
tion of skeletal abnormality, quality of life, need of hospitalizations
and mortality. The effects of immunogenicity on the safety and
effectiveness of enzyme replacement therapy with idursulfase need
to be better studied.
The effects of enzyme replacement therapy with idursulfase in
children under five years of age need to be further investigated,
given that the early introduction of therapy with consequent lim-
itation of the formation of lysosomal storage can potentially lead
to better outcomes in the evolution of the disease.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Muenzer 2006
Methods Multicentre, multinational, double-blind, randomised, placebo-controlled, 53-week
clinical trial
Participants Participants between the ages of 5 and 31 years with a diagnosis of MPS II based on both
clinical and biochemical criteria were enrolled in the study. Clinical criteria included
having any one of the following MPS II-related abnormalities: hepatosplenomegaly;
radiographic evidence of dysostosis multiplex; valvular heart disease; or evidence of
obstructive airway disease. The biochemical evidence of MPS II included a documented
deficiency in I2S enzyme activity of 10% of the lower limit of the normal range as
measured in plasma, fibroblasts, or leukocytes combined with a normal enzyme activity
level of another sulfatase. At baseline all participants were required to reproducibly
perform pulmonary function testing and have an abnormal FVC of 80% of predicted.
Participants who had a tracheostomy or who had received a bone marrow or cord blood
transplant were excluded from the study
Interventions Intravenous infusions of idursulfase weekly or EOW at a dose of 0.5 mg/kg, or weekly
infusions of placebo
Outcomes The primary efficacy endpoint in the trial measured changes from baseline to week 53,
combining % predicted FVC as a measure of respiratory function and the 6MWT as
a measure of functional capacity.The 6MWT was conducted in accordance with ATS
guidelines. The secondary efficacy outcome measurements were: passive JROM; liver
and spleen volume by MRI; urinary GAG levels and cardiac LVM by echocardiography.
All measurements were made at baseline, weeks 18, 36 and 53
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk We found no information about genera-
tion of randomisation sequence. Partici-
pants randomised equally to 1 of 3 treat-
ment arms, randomisation was stratified by
age and total disease score at baseline data
Allocation concealment (selection bias) Unclear risk Not cited.
Blinding (performance bias and detection
bias)
All outcomes
Low risk All participants received intravenous in-
fusion weekly. Participants randomised to
EOW idursulfase dosing received placebo
infusion during interveningweeks tomain-
tain blinding
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Muenzer 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94 (97.9%) of 96 participants completed
1 year of treatment. The two participants
who did not complete one year of treat-
ment died during the study: 1 participant
in the placebo group and 1 participant in
the idursulfaseweekly group.Neither death
was considered by the investigator to be re-
lated to the study drug
Selective reporting (reporting bias) Unclear risk There are concern about selective report-
ing, due important clinical outcomes (e.g.
LVM index and overnight AHI) were not
evaluated
Other bias Low risk The study apparently was free of other




ATS: American Thoracic Society
EOW: every other week
FVC: forced vital capacity
JROM: joint range of motion
I2S: iduronate-2-sulfatase
LVM: left ventricular mass
MRI: magnetic resonance imaging
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gutiérrez-Solana 2007 Narrative review.
Muenzer 2007 Phase I/II clinical trial that evaluated safety and dosing requirements in 12 people
Muenzer 2016 Phase I/II clinical trial that evaluated safety and dosing requirements of intrathecal idursulfase. No outcomes
of interest
Sohn 2013 Phase I/II clinical trial comparing a new formulation (idursulfase beta) with the formulation of idursulfase
currently available
Sohn 2015 Not a controlled study.
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(Continued)
Tylki-Szymanska 2008 Ongoing case series.
Characteristics of ongoing studies [ordered by study ID]
NCT02055118
Trial name or title A controlled, randomized, two-arm, open-label, assessor-blinded, multicenter study of intrathecal idursulfase-
IT administered in conjunctionwith Elaprase® in pediatric patients withHunter syndrome and early cognitive
impairment
Methods Randomized parallel, open label study.
Participants Participant male, ≥ 3 and < 18 years of age with documented diagnosis of MPS II, evidence at screening of
Hunter syndrome-related cognitive impairment and has received and tolerated a minimum of 4 months of
therapy with Elaprase® during the period immediately prior to screening.
Interventions Intervention: idursulfase-IT 10mg using intrathecal drug delivery device once a month for 52 weeks. Control:
standard care
Outcomes Change from baseline in the GCA score after 12 months of treatment at visit week 52, as obtained by DAS-
II testing
Starting date 17 January 2014.
Contact information MedInfo Shire HGT US ShireHGT Medicalinformation@shire.com.
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Idursulfase 0.5 mg/kg versus placebo




participants Statistical method Effect size
1 Six-minute walk test (6MWT)
(53 weeks)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Idursulfase 0.5 mg/kg
weekly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Idursulfase 0.5 mg/kg
EOW
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 % predicted FVC (53 weeks) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Idursulfase 0.5 mg/kg
weekly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Idursulfase 0.5 mg/kg
EOW
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Absolute FVC (L) (53 weeks) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Idursulfase 0.5 mg/kg
weekly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Idursulfase 0.5 mg/kg
EOW
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 6MWT+ % predicted FVC
(composite score) (53 weeks)
1 Mean Difference (Fixed, 95% CI) Totals not selected
4.1 Idursulfase 0.5 mg/kg
weekly
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Idursulfase 0.5 mg/kg
EOW
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Liver volume (%) (53 weeks) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Idursulfase 0.5 mg/kg
weekly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Idursulfase 0.5 mg/kg
EOW
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Spleen volume (%) (53 weeks) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Idursulfase 0.5 mg/kg
weekly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Idursulfase 0.5 mg/kg
EOW
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Urine GAG µg/mg creatinine
(%)(53 weeks)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Idursulfase 0.5 mg/kg
weekly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Idursulfase 0.5 mg/kg
EOW
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 One or more infusion-related
adverse events
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Idursulfase 0.5 mg/kg
weekly
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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8.2 Idursulfase 0.5 mg/kg
EOW
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Serious adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 Idursulfase 0.5 mg/kg
weekly
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Idursulfase 0.5 mg/kg
EOW
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 1 Six-minute walk test (6MWT)
(53 weeks).
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 1 Six-minute walk test (6MWT) (53 weeks)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 32 44.3 (69.6) 32 7.3 (53.8) 37.00 [ 6.52, 67.48 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 32 30.3 (58.3) 32 7.3 (53.8) 23.00 [ -4.49, 50.49 ]
-50 -25 0 25 50
Favours placebo Favours idursulfase
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Analysis 1.2. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 2 % predicted FVC (53 weeks).
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 2 % predicted FVC (53 weeks)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 32 3.45 (10) 32 0.75 (9.67) 2.70 [ -2.12, 7.52 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 32 0.004 (7.47) 32 0.75 (9.67) -0.75 [ -4.98, 3.49 ]
-10 -5 0 5 10
Favours placebo Favours idurdulfase
Analysis 1.3. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 3 Absolute FVC (L) (53 weeks).
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 3 Absolute FVC (L) (53 weeks)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 32 0.22 (0.28) 32 0.06 (0.17) 0.16 [ 0.05, 0.27 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 32 0.07 (0.17) 32 0.06 (0.17) 0.01 [ -0.07, 0.09 ]
-0.2 -0.1 0 0.1 0.2
Favours placebo Favours idursulfase
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Analysis 1.4. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 4 6MWT+ % predicted FVC
(composite score) (53 weeks).
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 4 6MWT+ % predicted FVC (composite score) (53 weeks)





N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 32 32 18.96 (6.47) 18.96 [ 6.28, 31.64 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 32 32 12.86 (6.17) 12.86 [ 0.77, 24.95 ]
-20 -10 0 10 20
Favours placebo Favours idursulfase
Analysis 1.5. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 5 Liver volume (%) (53 weeks).
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 5 Liver volume (%) (53 weeks)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 32 -25.3 (9.06) 32 -0.8 (9.06) -24.50 [ -28.94, -20.06 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 32 -24 (9.62) 32 -0.8 (9.06) -23.20 [ -27.78, -18.62 ]
-20 -10 0 10 20
Favours idursulfase Favours placebo
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Analysis 1.6. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 6 Spleen volume (%) (53 weeks).
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 6 Spleen volume (%) (53 weeks)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 32 -25.1 (13.58) 32 7.2 (23.77) -32.30 [ -41.79, -22.81 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 32 -19.8 (18.11) 32 7.2 (23.77) -27.00 [ -37.35, -16.65 ]
-50 -25 0 25 50
Favours idursulfase Favours placebo
Analysis 1.7. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 7 Urine GAG µg/mg creatinine
(%)(53 weeks).
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 7 Urine GAG g/mg creatinine (%)(53 weeks)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 32 -189.2 (146.03) 32 18.2 (169.23) -207.40 [ -284.85, -129.95 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 32 -155 (97.35) 32 18.2 (169.23) -173.20 [ -240.84, -105.56 ]
-200 -100 0 100 200
Favours idursulfase Favours placebo
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Analysis 1.8. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 8 One or more infusion-related
adverse events.
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 8 One or more infusion-related adverse events
Study or subgroup Idursulfase Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 22/32 21/32 1.05 [ 0.74, 1.48 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 22/32 21/32 1.05 [ 0.74, 1.48 ]
0.5 0.7 1 1.5 2
Favours idursulfase Favours placebo
Analysis 1.9. Comparison 1 Idursulfase 0.5 mg/kg versus placebo, Outcome 9 Serious adverse events.
Review: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
Comparison: 1 Idursulfase 0.5 mg/kg versus placebo
Outcome: 9 Serious adverse events
Study or subgroup Idursulfase Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Idursulfase 0.5 mg/kg weekly
Muenzer 2006 13/32 18/32 0.72 [ 0.43, 1.21 ]
2 Idursulfase 0.5 mg/kg EOW
Muenzer 2006 18/32 18/32 1.00 [ 0.65, 1.54 ]
0.1 0.2 0.5 1 2 5 10
Favours idursulfase Favours placebo
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A P P E N D I C E S
Appendix 1. Search strategy - Medline via PubMed
#1 Mucopolysaccharidosis II [mh]
#2 Mucopolysaccharidosis IIs
#3 Mucopolysaccharidoses IIs
#4 Hunter Syndrome Gargoylism










#15 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#16 Iduronate Sulfatase [Mh]
#17 Sulfoiduronate Sulfatase
#18 Iduronatesulfate Sulfohydrolase
#19 Hunter Corrective Factor
#20 Iduronate Sulfate Sulfatase
#21 Iduronato Sulfatasa
#22 Iduronato Sulfatase
#23 #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
# 24 randomized controlled trial [pt]
# 25 controlled clinical trial [pt]
#26 randomized [tiab]
#27 placebo [tiab]




#32 #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #29 OR #30 OR #31
#33#15 AND #23 AND #32
Appendix 2. Search strategy - LILACS via Bireme
#1 Mucopolysaccharidosis II [mh]
#2 Mucopolysaccharidosis IIs
#3 Mucopolysaccharidoses IIs
#4 Hunter Syndrome Gargoylism
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#14 Mucopolissacaridosis II
#15 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#16 Iduronate Sulfatase [Mh]
#17 Sulfoiduronate Sulfatase
#18 Iduronatesulfate Sulfohydrolase
#19 Hunter Corrective Factor
#20 Iduronate Sulfate Sulfatase
#21 Iduronato Sulfatasa
#22 Iduronato Sulfatase
#23 #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
#24 ((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL ORMh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Palavras]
#25 #15 AND #23 AND #24
Appendix 3. Search strategy - EMBASE via OVID
#1 Mucopolysaccharidosis II [mh]
#2 Mucopolysaccharidosis IIs
#3 Mucopolysaccharidoses IIs
#4 Hunter Syndrome Gargoylism










#15 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#16 Iduronate Sulfatase [Mh]
#17 Sulfoiduronate Sulfatase
#18 Iduronatesulfate Sulfohydrolase
#19 Hunter Corrective Factor
#20 Iduronate Sulfate Sulfatase
#21 Iduronato Sulfatasa
#22 Iduronato Sulfatase
#23 #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
#24 Controlled study/
#25 Randomization/
#26 Double blind procedure/
#27 Single blind procedure/
#28 Clinical trial/
#29 (clinical adj5 trial$).ti,ab,hw.
#30 ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw.
#31Placebo/
#32 Placebo$.ti,ab,hw.
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#41 (comparative adj5 trial$).ti,ab,hw.
#42 (control$ or prospectiv$ or volunteer$).ti,ab,hw.
#43 exp “Evaluation and Follow Up”/
#44 Prospective study/
#45 or/24-44
#46 animal/ not (human/ and animal/)
#47 45 not 46
#48 #15 OR #23 OR #47
WH A T ’ S N E W
Date Event Description
3 February 2016 New citation required but conclusions have not changed Minor changes have been made throughout the review;
the conclusions remain as per the original publication
3 February 2016 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
Disorders Group’s Inborn Errors of Metabolism Trials
Register identified 36 references. Searches of Embase,
PubMed and LILACS identified a further three refer-
ences
Two references have been added to ’Excluded studies’
(Muenzer 2016; Sohn 2015) and one to ’Ongoing stud-
ies’ (NCT02055118). An additional reference has been
added to one previously excluded study (Sohn 2013).
H I S T O R Y
Date Event Description
6 November 2013 New citation required but conclusions have not
changed
Minor changes have been made throughout the review.
6 November 2013 New search has been performed We carried out new searches but did not identify any
eligible trials for inclusion in the review
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C O N T R I B U T I O N S O F A U T H O R S
Edina Mariko Koga da Silva (EMKS) was responsible for the conception of this review.
EMKS and Regis Bruni Andrioli (RBA) were responsible for developing the search strategy and undertaking searches.
EMKS and Laercio Antonio da Silva (LAS) were responsible for screening search results, organising retrieval of papers, screening
retrieved papers against the inclusion criteria, appraising quality of papers and extracting data.
EMKS was responsible for data management for the review and entering data into RevMan. EMKS, LAS and Maria Wany Louzada
Strufaldi (MWLS) analysed and interpreted the data. EMKS wrote the results. EMKS, LAS and RBA provided a methodological
perspective; and MWLS provided a clinical perspective.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
During the completion of the systematic review we received valuable advice from experts on the definition of the outcomes. It was
therefore decided for improve the review and to change the primary outcomes to z score of height and weight and six-minutes walk
test (6MWT). For further information, please refer to Types of outcome measures.
Within the Results section of the review the final secondary outcome listed was not pre-defined, although this is a composite score of
two pre-defined outcomes. This was regarded as being of clinical interest and appropriate to be included within the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Drug Administration Schedule; Enzyme Replacement Therapy [∗methods]; Iduronate Sulfatase [∗administration & dosage]; Mu-
copolysaccharidosis II [∗drug therapy]; Randomized Controlled Trials as Topic; Rare Diseases [∗drug therapy; enzymology]
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MeSH check words
Humans; Male
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